Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study

Leukemia

Volumn 27, Issue 9, 2013, Pages 1874-1881

  Tefferi, A ^a   Rumi, E ^b   Finazzi, G ^c   Gisslinger, H ^d   Vannucchi, A M ^e   Rodeghiero, F ^f   Randi, M L ^g   Vaidya, R ^a   Cazzola, M ^b   Rambaldi, A ^c   Gisslinger, B ^d   Pieri, L ^e   Ruggeri, M ^f   Bertozzi, I ^g   Sulai, N H ^a   Casetti, I ^b   Carobbio, A ^c   Jeryczynski, G ^d   Larson, D R ^a   Mullauer L ^d   Pardanani, A ^a   Thiele, J ^h   Passamonti, F ⁱ   Barbui, T ^c   more..

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF FLORENCE   (Italy)

^f SAN BORTOLO HOSPITAL   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ OSPEDALE DI CIRCOLO   (Italy)

Author keywords

myelofibrosis; polycythemia; prognosis; survival; thrombocythemia

Indexed keywords

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CHROMOSOME ABERRATION; FEMALE; FOLLOW UP; HEMATOCRIT; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LEUKOCYTOSIS; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MYELOPHTHISIC ANEMIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RISK ASSESSMENT; SEX DIFFERENCE; SPLENOMEGALY; SURVIVAL; THROMBOCYTOSIS; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; LEUKEMIA; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; PROGNOSIS; ROC CURVE; YOUNG ADULT;

EID: 84883742082     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.163     Document Type: Article

References (46)

1. Vaquez H. Sur une forme speciale de cyanose s'accompanant d'hyperglobulie excessive et peristente (On a special form of cyanosis accompanied by excessive and persistent erythrocytosis). Compt rend Soc de biol and suppl note, Bull et mem Soc med d'hop de Paris, 3 ser, 1895;12:60 1892; 4: 384-388.
2. Osler W. Chronic cyanosis, with polycythemia and enlarged spleen: a new clinical entity. Am J Med Sci 1903; 126: 187-201.
3. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6: 372-375.
4. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976; 295: 913-916.
5. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148. (Pubitemid 40663494)
6. Tefferi A. Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up? Leukemia 2011; 25: 1059-1063.
7. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman LR, Berk PD, Berlin NI (eds) Polycythemia Vera and the Myeloproliferative Disorders. WB Saunders: Philadelphia, PA, USA, 1995, pp 166-194.
8. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
9. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
10. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29: 3179-3184.
11. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117: 5857-5859.
12. Tefferi A, Barbui T. Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. Leukemia 2013; e-pub ahead of print 30 April 2013; doi:10.1038/leu.2013.99.
13. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHOdefined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia 2013; e-pub ahead of print 5 April 2013; doi: 10.1038/leu.2013.74.
14. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120: 5128-5133, quiz 5252.
15. Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012; 120: 1197-1201.
16. Barbui T, Thiele J, Carobbio A, Passamonti F, Rumi E, Randi ML et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood 2012; 120: 569-571.
17. Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Mullauer L et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol 2012; 87: 669-672.
18. Carobbio A, Finazzi G, Thiele J, Kvasnicka HM, Passamonti F, Rumi E et al. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. Am J Hematol 2012; 87: 203-204.
19. Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 2012; 26: 716-719.
20. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437-438. (Pubitemid 351250553)
21. Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma 2010; 51: 199-212.
22. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
23. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 285-293.
24. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011; 29: 3907-3913.
25. Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007; 138: 354-358. (Pubitemid 47035399)
26. Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011; 25: 82-88.
27. Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer 2006; 106: 1985-1989. (Pubitemid 43673214)
28. Gangat N, Strand J, Lasho TL, Finke CM, Knudson RA, Pardanani A et al. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol 2008; 80: 197-200. (Pubitemid 351253455)
29. Swolin B, Weinfeld A, Westin J. A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 1988; 72: 386-395.
30. Tefferi A, Jimma T, Gangat N, Vaidya R, Begna KH, Hanson CA et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood 2011; 118: 4595-4598.
31. Tefferi A, Pardanani A, Gangat N, Begna KH, Hanson CA, Van Dyke DL et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia 2012; 26: 1439-1441.
32. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; e-pub ahead of print 26 April 2013; doi:101038/leu.2013.119.
33. Tefferi A, Jimma T, Sulai NH, Lasho TL, Finke CM, Knudson RA et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012; 26: 475-480.
34. Gangat N, Strand JJ, Lasho TL, Li CY, Pardanani A, Tefferi A. Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis. Am J Hematol 2008; 83: 451-453. (Pubitemid 351742791)
35. Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol 2013; 9; e-pub ahead of print 9 May 2013.
36. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.
37. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-2901.
38. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-1708.
39. Bonicelli G, Abdulkarim K, Mounier M, Johansson P, Rossi C, Jooste V et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol 2013; 160: 251-254.
40. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105: 2664-2670. (Pubitemid 40446255)
41. Zittoun R. Busulfan versus 32P in polycythaemia vera. Drugs Exp Clin Res 1986; 12: 283-285.
42. Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011; 118: 5227-5234.
43. Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012; 120: 4168-4171.
44. Laborde RR, Patnaik MM, Lasho TL, Finke CM, Hanson CA, Knudson RA et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia (CMML): independent prognostic impact in CMML. Leukemia 2013; e-pub ahead of print 5 April 2013; doi:101038/leu.2013.97.
45. Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013; 27: 1401-1403.
46. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.